A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

NCT04329429 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: RC48-ADC

Sponsor

RemeGen Co., Ltd.